Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. - Wikidata - wikimedia - TriplyDB

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.

http://www.wikidata.org/entity/Q38713147

about

Insights into the Link Between Obesity and Cancer.Cellular metabolism of tumor-associated macrophages - functional impact and consequences.Toll-Like Receptor Ligands and Interferon-γ Synergize for Induction of Antitumor M1 Macrophages.miR-148a-3p Mediates Notch Signaling to Promote the Differentiation and M1 Activation of Macrophages.The class I/IV HDAC inhibitor mocetinostat increases tumor antigen presentation, decreases immune suppressive cell types and augments checkpoint inhibitor therapy.Tumor-associated macrophages, nanomedicine and imaging: the axis of success in the future of cancer immunotherapy.Class IIa HDACs inhibitor TMP269 promotes M1 polarization of macrophages after spinal cord injury.Macrophages: Key orchestrators of a tumor microenvironment defined by therapeutic resistance.Innate and acquired immune surveillance in the postdissemination phase of metastasis.Repolarizing macrophages improves breast cancer therapy.Macrophages: The Road Less Traveled, Changing Anticancer Therapy.Immunotherapy for Breast Cancer: Current and Future Strategies.Chloroquine modulates antitumor immune response by resetting tumor-associated macrophages toward M1 phenotype.Beyond the M-CSF receptor - novel therapeutic targets in tumor-associated macrophages.An epigenetic modifier triggers therapeutic immune responses against breast cancer.Harnessing class II histone deacetylases in macrophages to combat breast cancer.Targeting Tumor-Associated Macrophages as a Potential Strategy to Enhance the Response to Immune Checkpoint Inhibitors.DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer.Immune oncology, immune responsiveness and the theory of everything.Diamonds in the Rough: Harnessing Tumor-Associated Myeloid Cells for Cancer Therapy TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation

P2860

Q39256853-60CA97D2-B98C-45C7-9A71-EC0D4AF9BDAA Q40108243-C8617BEB-7AFD-4CF3-8A74-1E60B7BB6353 Q45395222-D5F9164C-0BF6-4651-80D4-2C28666B8AE7 Q46272050-C4D2020A-92ED-4927-BB7B-9C0AAD60878F Q47417938-7373746E-DDAB-4B34-873F-2EC5CED15B74 Q47962563-76F2EC41-C3D8-46B8-984A-B91E965D96A3 Q48114670-A3B218D5-D88C-4815-83E5-56F681178C37 Q49609112-B5157FE0-C18E-474A-8689-CD376780F330 Q50048813-309F7760-6099-4CB9-821B-EE20AD0CA6E9 Q50442606-E54CA6EB-C8F4-4FAD-A8D6-D2D766E35707 Q52321369-997266A1-164C-4AAF-80F6-E739C14BA08A Q52587066-02D9B0E9-B223-4050-B884-F58F2DAB0BC5 Q52680719-ED54F667-B4B2-4D6B-9F13-72D2023A4BF9 Q53099163-EB88AF23-1EDD-47CA-BC66-99930AB4AD18 Q53204470-9A0B9A32-25B6-4517-987E-A704AD88C1C3 Q53984312-BC33A795-3C10-4225-80A9-15D301B669BB Q55019711-609B0367-A6C2-4ECC-A5BA-95A06CFA260E Q55425717-E3524CF5-5F2A-4893-A721-FCA0708B3EBC Q55487467-5483B25C-8759-4C9A-849C-99B83DB5D4AB Q57817490-D0295C17-F35D-4590-B7E4-4244B03512C8 Q57826568-1FA5E528-7226-4D64-9D4D-675A1C2F9AC8 Q58780996-8BCF2321-55A7-4D5F-A16E-27B63E0CD9C4 Q59132144-71AA5159-87E7-4E5C-93B6-911544FA6493

P2860

Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages.

http://www.wikidata.org/entity/Q38713147

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Class IIa HDAC inhibition redu ...... rough anti-tumour macrophages.

@en

type

label

Class IIa HDAC inhibition redu ...... rough anti-tumour macrophages.

@en

prefLabel

Class IIa HDAC inhibition redu ...... rough anti-tumour macrophages.

@en

P1433

Q38713147-55C8AD40-81B7-4006-B6AD-9B79D88AAB90

P1476

Q38713147-CED64224-5781-4498-B9D1-E0CCB1A5BF3D

P2093

Q38713147-0093180F-7B1A-4807-A846-15182E72C290

Q38713147-163BC91E-99AF-43BF-B6FD-11049CE8B383

Q38713147-17D493AA-F929-4482-98BC-BCE47E10014F

Q38713147-19D6D07A-70CB-4BF5-A840-099476E4D163

Q38713147-3C0BF0E9-8318-479F-8972-36EF07974437

Q38713147-6791B985-0352-41FC-9605-86E7F8D3527D

Q38713147-7028E461-0EF1-4F31-970B-FCC25DB4F00F

Q38713147-78418BD9-98B2-4ECB-88B5-57D45AF4C2F5

Q38713147-86EA9876-6D5B-471F-9121-4F07E09466FF

Q38713147-888D848D-BEB0-44A5-A3F1-CF9C3B49FB04

P2860

Q38713147-0E9E19BF-F85A-4E16-9A90-E637962B781B

Q38713147-141E6D53-D4F9-4DDF-82AE-B32273E2E97A

Q38713147-1727CAA7-28CE-47A5-B200-599508AFE2AB

Q38713147-19C2D646-B9AA-4583-80B7-39F86CFFAD47

Q38713147-38C56164-3B61-46E1-8585-CD082B5C30B1

Q38713147-4B5912E9-3B7B-46B1-8D2F-37CA5FC51845

Q38713147-53FB83B8-3089-4BC0-8A1C-204D9953C55C

Q38713147-5857ED49-B3B9-42FE-B467-614FC825B241

Q38713147-61B2CFE5-95D0-4EB7-9B05-26D0A32EDF3B

Q38713147-64192137-DE86-4A8F-B155-351306E95135

P2888

Q38713147-3DEF7257-39A6-4F1D-AB1D-36A0BE0F1178

P304

Q38713147-7DEB42A3-7460-44B6-B39E-0D7CA0F7A729

P31

Q38713147-6A670A44-41B9-4E4B-B306-F6FB617CC6E2

P356

Q38713147-4B685D0F-8B0E-4394-8D7C-514CE3FE7BB3

P407

Q38713147-7366A4A6-50F1-4FB0-B047-93E4366C24F1

P433

Q38713147-F1E297E5-A1C9-46F0-8271-8F248F689A36

P478

Q38713147-4BAB83D6-4B91-477D-8B12-6ACCC1383866

P577

Q38713147-1E8EFAF7-9059-4736-A08C-576F9F51DB30

P6179

Q38713147-73D8B94B-2A5F-49FB-AC52-4BFC54A3202C

P698

Q38713147-7C6FEA8C-508D-4E60-8D8C-9507170AE576

P356

P1433

P1476

Class IIa HDAC inhibition redu ...... rough anti-tumour macrophages.

@en

P2093

Alaba Sotayo

http://www.w3.org/2001/XMLSchema#string

Alexandra L Pourzia

http://www.w3.org/2001/XMLSchema#string

Anthony Letai

http://www.w3.org/2001/XMLSchema#string

Holly E Ponichtera

http://www.w3.org/2001/XMLSchema#string

Jennifer L Guerriero

http://www.w3.org/2001/XMLSchema#string

Jessica A Castrillon

http://www.w3.org/2001/XMLSchema#string

Mercedes Lobera

http://www.w3.org/2001/XMLSchema#string

Michael A Nolan

http://www.w3.org/2001/XMLSchema#string

Roderick T Bronson

http://www.w3.org/2001/XMLSchema#string

Ruben D Carrasco

http://www.w3.org/2001/XMLSchema#string

P2860

NIH Image to ImageJ: 25 years of image analysis

Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR

Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

Selective class IIa histone deacetylase inhibition via a nonchelating zinc-binding group

Discovery of I-BRD9, a Selective Cell Active Chemical Probe for Bromodomain Containing Protein 9 Inhibition

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

Tumour-educated macrophages promote tumour progression and metastasis

Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy

P2888

P304

428-432

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NATURE21409

http://www.w3.org/2001/XMLSchema#string

P407

P433

7645

http://www.w3.org/2001/XMLSchema#string

P478

543

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084128541

http://www.w3.org/2001/XMLSchema#string

P698

28273064

http://www.w3.org/2001/XMLSchema#string